Oral AR1001 Hits Primary Endpoint in Prespecified Early AD Monotherapy Cohort at CTAD 2026

BOSTON — Topline 52-week results from the global Phase 3 POLARIS-AD trial presented at the Clinical Trials on Alzheimer’s Disease (CTAD 2026) conference show that AR1001, an investigational once-daily oral candidate from AriBio, slowed cognitive and functional decline by 31% in a prespecified monotherapy subgroup of patients with early Alzheimer’s disease, while missing statistical significance in the overall study population.

Presented on November 16 by trial lead Sharon Sha, MD, director of the Stanford Center for Memory Disorders, the findings drew coverage in The Washington Post and The Guardian as analysts and clinicians weighed the clinical appeal of an oral small molecule against the mixed readout across trial populations.

Trial Design and Primary Efficacy Readout

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply